Zoetis Inc. (ZTS) Given Consensus Recommendation of “Buy” by Analysts
Zoetis Inc. (NYSE:ZTS) has been assigned an average rating of “Buy” from the nineteen research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $65.12.
A number of analysts have commented on the stock. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 target price on shares of Zoetis in a report on Wednesday, September 6th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 target price on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Friday, August 25th. Finally, Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, August 24th.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/17/zoetis-inc-zts-given-consensus-recommendation-of-buy-by-analysts.html.
Zoetis (NYSE ZTS) traded down 0.08% on Friday, reaching $65.20. 2,115,398 shares of the company were exchanged. The firm has a 50-day moving average of $62.29 and a 200 day moving average of $59.39. The firm has a market capitalization of $31.89 billion, a P/E ratio of 36.86 and a beta of 1.02. Zoetis has a 12-month low of $46.86 and a 12-month high of $65.83.
Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the prior year, the company earned $0.49 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. On average, equities analysts predict that Zoetis will post $2.34 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in Zoetis by 8.2% during the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after acquiring an additional 389,260 shares in the last quarter. Gladstone Capital Management LLP purchased a new position in Zoetis during the second quarter valued at $3,134,000. Swiss National Bank grew its stake in Zoetis by 8.1% during the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after acquiring an additional 133,900 shares in the last quarter. Harbour Capital Advisors LLC grew its stake in Zoetis by 19.8% during the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Hermes Investment Management Ltd. grew its stake in Zoetis by 80.3% during the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after acquiring an additional 105,276 shares in the last quarter. 93.31% of the stock is owned by institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.